Plasma methoxytyramine: clinical utility with metanephrines for diagnosis of pheochromocytoma and paraganglioma by Rao, Dipti et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2017
Plasma methoxytyramine: clinical utility with metanephrines for diagnosis
of pheochromocytoma and paraganglioma
Rao, Dipti; Peitzsch, Mirko; Prejbisz, Aleksander; Hanus, Katarzyna; Fassnacht, Martin; Beuschlein,
Felix; Brugger, Christina; Fliedner, Stephanie; Langton, Katharina; Pamporaki, Christina; Gudziol,
Volker; Stell, Anthony; Januszewicz, Andrzej; Timmers, Henri J L M; Lenders, Jacques W M;
Eisenhofer, Graeme
Abstract: CONTEXT: Measurements of plasma methoxytyramine, the O-methylated dopamine metabo-
lite, are useful for detecting rare dopamine-producing pheochromocytomas and paragangliomas (PPGLs)
and head and neck paragangliomas (HNPGLs), but utility for screening beyond that achieved using
standard measurements of normetanephrine and metanephrine is unclear. OBJECTIVE: Evaluation
of the additional utility of methoxytyramine compared to plasma normetanephrine and metanephrine
for diagnosis of PPGLs and HNPGLs. DESIGN: Comparative prospective study. METHODS: Com-
parison of mass spectrometric-based measurements of plasma methoxytyramine, normetanephrine and
metanephrine in 1963 patients tested for PPGLs at six tertiary medical centers according to reference
intervals verified in 423 normotensive and hypertensive volunteers. RESULTS: Of the screened patients,
213 had PPGLs and 38 HNPGLs. Using an upper cut-off of 0.10 nmol/L for methoxytyramine, 0.45
nmol/L for metanephrine and age-specific upper cut-offs for normetanephrine, diagnostic sensitivity with
the addition of methoxytyramine increased from 97.2% to 98.6% for patients with PPGLs and from 22.1%
to 50.0% for patients with HNPGLs, with a small decrease in specificity from 95.9% to 95.1%. Addi-
tion of methoxytyramine did not significantly alter areas under receiver operating characteristic curves
for patients with PPGLs (0.984 vs 0.991), but did increase (P < 0.05) areas for patients with HNPGLs
(0.627 vs 0.801). Addition of methoxytyramine also increased the proportion of patients with PPGLs who
showed highly positive predictive elevations of multiple metabolites (70.9% vs 49.3%). CONCLUSIONS:
While the benefit of additional measurements of plasma methoxytyramine for the detection of PPGLs is
modest, the measurements do assist with positive confirmation of disease and are useful for the detection
of HNPGLs.
DOI: https://doi.org/10.1530/EJE-17-0077
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-138824
Published Version
 
 
Originally published at:
Rao, Dipti; Peitzsch, Mirko; Prejbisz, Aleksander; Hanus, Katarzyna; Fassnacht, Martin; Beuschlein, Fe-
lix; Brugger, Christina; Fliedner, Stephanie; Langton, Katharina; Pamporaki, Christina; Gudziol, Volker;
Stell, Anthony; Januszewicz, Andrzej; Timmers, Henri J L M; Lenders, Jacques WM; Eisenhofer, Graeme
(2017). Plasma methoxytyramine: clinical utility with metanephrines for diagnosis of pheochromocytoma
and paraganglioma. European Journal of Endocrinology, 177(2):103-113.
DOI: https://doi.org/10.1530/EJE-17-0077
2
Eu
ro
p
ea
n
 J
o
u
rn
al
 o
f 
En
d
o
cr
in
o
lo
g
y
Open Access
DOI: 10.1530/EJE-17-0077
This work is licensed under a Creative Commons 
Attribution 3.0 Unported License.Published by Bioscientifica Ltd.
© 2017 The authors
Printed in Great Britain
www.eje-online.org
Plasma methoxytyramine: clinical utility with 
metanephrines for diagnosis of 
pheochromocytoma and paraganglioma
Dipti Rao1, Mirko Peitzsch2, Aleksander Prejbisz3, Katarzyna Hanus3, 
Martin Fassnacht4, Felix Beuschlein5, Christina Brugger5, Stephanie Fliedner6, 
Katharina Langton7, Christina Pamporaki7, Volker Gudziol8, Anthony Stell9, 
Andrzej Januszewicz3, Henri J L M Timmers1, Jacques W M Lenders1,7 and 
Graeme Eisenhofer2,7
1Department of Internal Medicine, Radboud University Medical Centre, Nijmegen, The Netherlands, 2Institute of 
Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus, Technische Universität Dresden, 
Dresden, Germany, 3Department of Hypertension, Institute of Cardiology, Warsaw, Poland, 4Department of 
Endocrinology, University Hospital Würzburg, Würzburg, Germany, 5Department of Endocrinology, University 
Hospital München, München, Germany, 6First Department of Medicine, University Medical Center Schleswig-Holstein, 
Lübeck, Germany, Departments of 7Medicine III and 8Otorhinolaryngology, University Hospital Carl Gustav Carus, 
Technische Universität Dresden, Dresden, Germany, and 9Melboune eResearch Group, University of Melbourne, 
Melbourne, Australia
Abstract
Context: Measurements of plasma methoxytyramine, the O-methylated dopamine metabolite, are useful for detecting 
rare dopamine-producing pheochromocytomas and paragangliomas (PPGLs) and head and neck paragangliomas 
(HNPGLs), but utility for screening beyond that achieved using standard measurements of normetanephrine and 
metanephrine is unclear.
Objective: Evaluation of the additional utility of methoxytyramine compared to plasma normetanephrine and 
metanephrine for diagnosis of PPGLs and HNPGLs.
Design: Comparative prospective study.
Methods: Comparison of mass spectrometric-based measurements of plasma methoxytyramine, normetanephrine and 
metanephrine in 1963 patients tested for PPGLs at six tertiary medical centers according to reference intervals verified 
in 423 normotensive and hypertensive volunteers.
Results: Of the screened patients, 213 had PPGLs and 38 HNPGLs. Using an upper cut-off of 0.10 nmol/L for 
methoxytyramine, 0.45 nmol/L for metanephrine and age-specific upper cut-offs for normetanephrine, diagnostic 
sensitivity with the addition of methoxytyramine increased from 97.2% to 98.6% for patients with PPGLs and from 
22.1% to 50.0% for patients with HNPGLs, with a small decrease in specificity from 95.9% to 95.1%. Addition 
of methoxytyramine did not significantly alter areas under receiver operating characteristic curves for patients 
with PPGLs (0.984 vs 0.991), but did increase (P < 0.05) areas for patients with HNPGLs (0.627 vs 0.801). Addition 
of methoxytyramine also increased the proportion of patients with PPGLs who showed highly positive predictive 
elevations of multiple metabolites (70.9% vs 49.3%).
Conclusions: While the benefit of additional measurements of plasma methoxytyramine for the detection of PPGLs is 
modest, the measurements do assist with positive confirmation of disease and are useful for the detection of HNPGLs.
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Introduction
Pheochromocytomas and paragangliomas (PPGL) are 
catecholamine-producing neuroendocrine tumors 
respectively derived from intra-adrenal and extra-adrenal 
chromaffin cells (1). Head and neck paragangliomas 
(HNPGL) in contrast do not display chromaffin cell 
phenotypic features or usually produce significant 
amounts of catecholamines (2). Catecholamines produced 
within chromaffin cells and their tumor derivatives 
are metabolized within the same cells by catechol-O-
methyltransferase, a continuous process that operates 
independently of catecholamine secretion, explaining 
why the O-methylated metabolites provide superior 
biomarkers for PPGLs compared to their catecholamine 
precursors (3). While norepinephrine and epinephrine 
are respectively metabolized to normetanephrine and 
metanephrine (collectively termed metanephrines), 
dopamine is metabolized to methoxytyramine.
According to The Endocrine Society Clinical Practice 
Guidelines (4), initial biochemical testing for PPGLs should 
include measurements of plasma-free metanephrines 
or urinary fractionated metanephrines, with reference 
intervals and measurements for the former test 
preferentially carried out using blood samples collected 
in the supine position. Over the past decade, these tests 
have superseded measurements of plasma or urinary 
catecholamines for diagnosis of PPGLs. Nevertheless, 
since measurements of urinary catecholamines commonly 
include dopamine, it has been suggested that additional 
catecholamine measurements can be useful for diagnosis 
of dopamine-producing tumors (5). This, however, 
ignores the fact that most dopamine in urine is derived 
from renal uptake and decarboxylation of circulating 
L-dopa (6). Consequently, measurements of plasma 
methoxytyramine are superior to urinary dopamine for 
the detection of dopamine-producing tumors (7).
Measurements of plasma methoxytyramine have 
been introduced for identifying patients with metastatic 
PPGLs, HNPGLs and tumors due to mutations of genes 
encoding succinate dehydrogenase subunits (8, 9, 10). 
Nevertheless, the measurements are not widely offered 
as part of routine measurements of metanephrines. In 
part, this reflects difficulty in measuring the very low 
concentrations of free methoxytyramine in plasma, 
a problem now overcome by a new generation of mass 
spectrometers that offer higher analytical sensitivity than 
previously available. However, even with this problem 
solved, it remains unclear how much additional diagnostic 
utility, if any, measurements of methoxytyramine add to 
standard measurements of metanephrines. In particular, 
since plasma metanephrines offer already high diagnostic 
sensitivity for PPGLs, a reasonable concern of including 
methoxytyramine is that any additional small increase 
in disease detection may be entirely negated by increased 
numbers of false-positive results.
The above concern is compounded by reported 
experience of others with measurements of plasma 
metanephrines, where high numbers of false-positive 
results erode confidence that positive results can be 
reliably used to predict the presence of PPGLs (5, 11, 
12). Problems with false-positive results can be mitigated 
by appropriately implemented reference intervals and 
attention to preanalytics, specially blood sampling in 
the supine position (13). For measurements of plasma 
methoxytyramine, it is important that patients are 
sampled after an overnight fast (14).
With the above considerations in mind, the present 
study used data collected from 1963 patients of an ongoing 
prospective study to assess the diagnostic utility of including 
measurements of plasma methoxytyramine with standard 
measurements of plasma-free metanephrines. An additional 
423 normotensive and hypertensive volunteers were 
included to establish mass-spectrometric-derived reference 
intervals for methoxytyramine and validate reference 
intervals established for metanephrine and normetanephrine 
measured using a different analytical method (15).
Subjects and methods
Subjects
Subjects included 1963 patients screened for PPGLs in a 
multicenter prospective study (Prospective Monoamine-
producing Tumor study) according to a protocol and 
standard-operating procedures available online (https://
pmt-study.pressor.org). Patients were enrolled at 6 tertiary 
medical centers: (1) University Hospital Carl Gustav 
Carus Dresden, Germany; (2) University Medical Centre 
Schleswig-Holstein Lübeck, Germany; (3) University 
Hospital of Münich, Germany; (4) University Hospital 
of Würzburg, Germany; (5) Radboud University Medical 
Centre, Nijmegen, the Netherlands; and (6) the Institute 
of Cardiology, Warsaw, Poland. Enrolment was according 
to several criteria establishing suspicion or risk for PPGLs: 
(1) signs and symptoms of catecholamine excess (n = 794); 
(2) therapy-resistant hypertension (n = 451); (3) findings 
of an incidentaloma (n = 426); (4) hereditary risk of PPGL 
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(n = 104); (5) previous history of PPGL (n = 178) and (6) 
other (n = 10). The reference population consisted of 423 
normotensive and hypertensive volunteers (Table  1). 
Subjects taking tricyclic antidepressants, L-dopa or other 
medications known to raise plasma concentrations of 
O-methylated metabolites were excluded. All subjects 
provided written informed consent.
Tumor diagnosis and follow-up
Of the 1963 patients screened for PPGLs, tumors were 
confirmed in 251, including 213 with PPGLs and 38 
with HNPGLs (Table 1). HNPGLs were mainly diagnosed 
based on testing because of hereditary risk or previous 
history of tumors, with routine surveillance among those 
at hereditary risk including imaging studies. PPGLs and 
HNPGLs were confirmed by pathological examination of 
surgically resected or biopsied tumor tissue (HNPGLs) or 
by diagnosis of inoperable metastatic disease based on 
functional imaging.
Of the patients without an initial diagnosis of PPGL, 
follow-up information to exclude or confirm previously 
undiagnosed PPGL was available in 1087 patients. Of 
those patients, PPGLs were excluded based on findings 
that all signs and symptoms were resolved (n = 408), 
an alternative diagnosis (n = 289), negative follow-up 
biochemical testing (n = 283) including negative results of 
clonidine suppression tests in patients with initial positive 
results (n = 30), alternative pathological diagnosis of a 
resected incidentaloma (n = 44), negative imaging studies 
(n = 45) or other information derived from follow-up 6 or 
more months after initial screening (n = 13). Four patients 
were diagnosed with PPGLs and one with a HNPGL on 
follow-up one or more years after initial testing.
Blood sampling and biochemical testing
Blood samples were collected from patients and volunteers 
using a forearm venous cannula with subjects supine 
for at least 20 min before sampling. Blood samples were 
stored at −80°C until analysis at Dresden. Plasma-free 
normetanephrine, metanephrine and methoxytyramine 
were determined by liquid chromatography with 
tandem mass spectrometry (LC–MS/MS), as described 
elsewhere (16) and modified for measurements of 
methoxytyramine (17).
Statistical analysis
Data from the reference population was used to 
validate upper cut-offs (UCs) previously established 
in a large population of over 5000 subjects for plasma 
metanephrines measured using a different analytical 
method (15). For methoxytyramine, UCs were determined 
using the distribution of the reference population. 
Differences between normo- and hypertensive reference 
subjects were tested by multivariate analysis after 
logarithmic transformation with inclusion of age and 
gender in the model.
True-positive results were defined in patients with 
tumors by plasma concentrations of any metabolite 
or combinations of metabolites equal to or above the 
UCs, whereas false-negative results were defined as 
concentrations of all metabolites below the UCs. False-
positive results were defined in patients without tumors 
by plasma concentrations of any metabolite equal to or 
above the UCs, whereas true-negative results were defined 
as concentrations of all metabolites below the UCs. 
Diagnostic sensitivity was estimated from the percentage 
of true-positive results among the total of true-positive 
and false-negative results for patients with PPGLs. 
Diagnostic specificity was estimated from the percentage 
of true-negative results among the total of true-negative 
and false-positive results.
Receiver operating characteristic (ROC) curves were 
constructed based on multivariable logistic regression 
models including normetanephrine, metanephrine and 
methoxytyramine as characteristics, with comparisons 
of areas under curves (AUC) to assess differences in 
diagnostic test performance. Positive predictive values 
(posttest probability of a positive result) were calculated 
across prevalence rates (pretest probability) using positive 
likelihood ratios. Curves relating the prevalence rates and 
positive predictive values were constructed for different 
combinations of metabolites. Statistical analyses utilized 
the JMP statistics software package (SAS Institute Inc., 
Cary, NC, USA).
Table 1 Characteristics of reference and patient populations.
 
Group
Reference No tumors PPGLs HNPGLs
n 423 1712 213 38
Age, median 
and (range)
45 (18–81) 54 (10–93) 50 (11–82) 48 (26–75)
Gender, F/M 238/185 852/860 117/96 22/16
F, females; HNPGLs, head and neck paragangliomas; M, males; 
PPGLs, pheochromocytomas and paragangliomas.
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Results
Reference population and upper cut-offs
Plasma concentrations of normetanephrine did not differ 
between men and women, whereas concentrations of 
metanephrine and methoxytyramine were respectively 
30% and 9% higher in men than women (Table  2). 
Plasma concentrations of all three metabolites showed 
significant positive relationships with age, the strongest 
for normetanephrine (r = 0.321, P < 0.0001) and weaker 
relationships for methoxytyramine (r = 0.196, P < 0.0001) 
and metanephrine (r = 0.130; P = 0.0065).
Only normetanephrine, however, showed consistent 
age-related increases across age groups (Table  2); these 
differences and the relationship of normetanephrine with 
age showed close agreement with previously reported 
data in a larger reference population (15), validating the 
age-specific reference intervals of that population for 
use with LC–MS/MS-derived measurements (Fig.  1A). 
Thus, for plasma normetanephrine, age-specific 
UCs were selected according to a previously derived 
formula (UC nmol/L = 0.000002074 × age3 + 0.54; UC pg/
mL = 0.0003792 × age3 + 98.9), but with maximum UC of 
1.09 nmol/L (200 pg/mL) at age 65 (Fig. 1A), as used in the 
routine diagnostic service offered at Dresden since 2013. 
The previously established UC of 0.45 nmol/L (88 pg/mL) 
for metanephrine (15) was also validated by the current 
reference population, with only one subject showing a 
plasma concentration of metanephrine above that UC. 
The UC for methoxytyramine was selected at 0.10 nmol/L 
(17 pg/mL) based on the highest concentration in the 
reference group.
Although plasma concentrations of methoxytyramine, 
normetanephrine and metanephrine were all higher 
(P < 0.02) in hypertensive than normotensive groups 
of the reference population, these groups also differed 
(P < 0.0001) considerably in age (Table  2). Using 
multivariate analyses to correct for age, there were no 
differences in plasma concentrations of metanephrine 
and methoxytyramine between normotensives and 
hypertensives. In contrast, differences in plasma 
concentrations of normetanephrine persisted (P = 0.0044), 
but with correction for age, were reduced from 26% to 12% 
higher values in hypertensives than normotensives. The 
positive relationship of age with plasma normetanephrine 
remained highly significant (P < 0.0001).
Positive test results
Plasma concentrations of methoxytyramine and 
metanephrine were respectively increased above UCs in 
45.5% and 53.5% of patients with PPGLs and 31.6% and 
none of the patients with HNPGLs, compared to 1.1% and 
0.4% of patients without tumors (Fig.  2A and C). With 
application of age-specific UCs, plasma normetanephrine 
was increased in 93.0% of patients with PPGLs and 21.1% 
of patients with HNPGLs compared to 3.9% of patients 
without tumors (Figs 1B and 2B).
Diagnostic sensitivity and specificity
The standard combination of normetanephrine and 
metanephrine yielded a diagnostic sensitivity of 97.2% for 
PPGLs compared to 22.1% for HNPGLs at a specificity of 
95.9% (Table 3). With the addition of methoxytyramine, 
diagnostic specificity decreased to 95.1%, while sensitivity 
increased to 98.6% for the detection of PPGLs and to 
50.0% for the detection of HNPGLs.
Table 2 Plasma concentrations (medians with ranges) for methoxytyramine, normetanephrine and metanephrine across the 
reference population.
  n Age, median Methoxytyramine (nmol/L) Normetanephrine (nmol/L) Metanephrine (nmol/L)
All subjects 423 45 0.028 (0.008–0.100) 0.340 (0.129–1.055) 0.151 (0.030–0.449)
Women 238 45 0.027 (0.008–0.078) 0.336 (0.129–0.946) 0.135 (0.030–0.449)
Men 185 46 0.029 (0.009–0.100)* 0.342 (0.156–1.055) 0.176 (0.058–0.405)**
18–29 years 83 25 0.026 (0.008–0.063) 0.281 (0.129–0.580) 0.138 (0.030–0.264)
30–39 years 65 35 0.028 (0.014–0.089) 0.301 (0.129–0.698) 0.139 (0.047–0.334)
40–49 years 116 45 0.028 (0.014–0.078) 0.320 (0.136–0.788) 0.151 (0.059–0.449)
50–59 years 100 54 0.024 (0.008–0.100) 0.368 (0.174–0.873) 0.164 (0.053–0.405)
>60 years 59 63 0.031 (0.014–0.065) 0.383 (0.156–1.055) 0.159 (0.037–0.329)
Normotensive 161 37 0.028 (0.008–0.100)¥ 0.288 (0.129–0.788)¥¥ 0.141 (0.042–0.449)¥
Hypertensive 262 50 0.029 (0.009–0.088) 0.362 (0.129–1.055) 0.161 (0.030–0.405)
*Indicates difference (P = 0.0031) between men and women; **indicates difference (P < 0.001) between men and women; ¥indicates difference (P < 0.05) 
between normotensive and hypertensive subjects; ¥¥indicates difference (P < 0.0001) between normotensive and hypertensive subjects.
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The increased diagnostic sensitivity with inclusion of 
methoxytyramine reflected 3 patients with PPGLs and 11 
patients with HNPGLs who showed increases in plasma 
concentrations of methoxytyramine above the UCs, 
but no increases above UCs for either normetanephrine 
or metanephrine. All the three patients with PPGLs 
and solitary increases in plasma methoxytyramine had 
mutations of the gene for succinate dehydrogenase subunit 
D and all presented with extra-adrenal paragangliomas, 
including one patient who also had a HNPGL.
For diagnosis of PPGLs, areas under ROC curves did 
not differ with and without methoxytyramine in the test 
panel (0.991 vs 0.984), whereas for HNPGLs, areas under 
ROC curves were higher (P < 0.05) with than without 
methoxytyramine (0.801 vs 0.627) (Fig. 3).
False-negative results
Although half of all patients with HNPGLs had 
concentrations of all 3 metabolites under UCs, only three 
of the 213 patients with PPGLs had entirely negative 
test results. One patient had a single 1.2 cm lymph node 
metastasis resected one year after biochemical testing 
and 3 years after resection of a 7 × 8 × 5 cm biochemically 
positive adrenal tumor. The two other patients had 
large non-functional tumors. One patient with an SDHB 
mutation had an 11.3 × 7.6 × 9.3 cm pelvic paraganglioma 
with extensive metastases that remained biochemically 
negative on repeated testing. The other patient had a 
4.8 cm local recurrence and rapidly progressive metastatic 
disease at one year after the removal of a 17 × 10 × 10 cm 
retroperitoneal tumor.
Follow-up diagnosis of tumors
There were five patients who were not diagnosed with 
tumors until follow-up, including the patient described 
above with the 1.2 cm lymph node metastasis and false-
negative results. Another patient with a HNPGL and false-
negative results showed increases of normetanephrine 
above age-specific UCs (1.08 nmol/L; 197 pg/mL) from 
0.64 nmol/L (118 pg/mL) to 1.24 nmol/L (227 pg/mL) one 
year after initial testing when metastases also became 
evident. Two patients aged 11 and 19  years had small 
increases of normetanephrine (0.76 and 0.59 nmol/L; 
140 and 108 pg/mL) above age-specific UCs (0.54 and 
0.55 nmol/L; 99 and 101 pg/mL), but PPGLs remained 
undiagnosed until follow-up. The younger patient with 
von Hippel–Lindau syndrome showed a further increase 
in normetanephrine to 1.05 nmol/L (192 pg/mL) one 
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Figure 1
Relationships of age with plasma concentrations of 
normetanephrine. Panel A illustrates age relationships for 
subjects of the reference population (solid black dots) and 
patients tested for PPGLs without evidence of tumors (solid gray 
dots). Panel B illustrates age relationships with normetanephrine 
on a logarithmic scale for patients with PPGLs and positive results 
for normetanephrine alone (solid black square), methoxytramine 
or methoxytyramine and normetanephrine (solid black upward 
triangle), metanephrine or metanephrine and normetanephrine 
(solid black downward triangle), all three metabolites (solid 
black diamond) or no metabolites (solid gray dot) compared with 
patients without tumors (solid black dot). The dashed lines 
indicate age-specific UCs of reference intervals derived from the 
formula (UC nmol/L = 0.000002074 × age3 + 0.54) for patients 
5 years to a maximum of 65 years.
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year following initial testing, after which a clonidine test 
and imaging confirmed a subsequently resected adrenal 
pheochromocytoma. The other patient with multiple 
endocrine neoplasia type 2 showed respective increases of 
normetanephrine from 0.59 to 1.00 nmol/L (108–183 pg/
mL) and of metanephrine from 0.43 to 7.79 nmol/L 
(85–1536 pg/mL) at 18  months after initial testing at 
which time a 4 cm cystic adrenal tumor was removed. 
The fifth patient had initially elevated normetanephrine 
concentrations of 1.70 nmol/L (312 pg/mL) and normal 
concentrations of methoxytyramine (0.05 nmol/L; 9 pg/
mL) that respectively increased to 8.65 and 0.30 nmol/L 
(1447 and 50 pg/mL) two years later when metastatic 
disease was diagnosed.
Positive predictive values
Among the patients with PPGLs, 45.5% had increases of 
both normetanephrine and methoxytyramine above UCs 
and 49.3% had increases of both normetanephrine and 
metanephrine above UCs compared to less than 0.3% 
of patients without tumors (Fig.  4). With the addition 
0.01
0.1
1
10
100
REF        NO TUM         PPGL         HNPGL    
Pl
as
m
a m
et
ho
xy
ty
ra
m
in
e(
nm
ol
/L
)
A
0.1
1
10
100
0.1
0.01
1
10
100
REF        NO TUM         PPGL         HNPGL    
Pl
as
m
a n
or
m
et
an
ep
hr
in
e(
nm
ol
/L
)
B
REF        NO TUM         PPGL         HNPGL    
Pl
as
m
a m
et
an
ep
hr
in
e (
nm
ol
/L
)
C
0.028 0.029
0.086 0.069
0.340 0.363
3.499
0.444
0.151 0.152 0.135
0.541
Figure 2
Dot plots for plasma concentrations of methoxytyramine (A), 
normetanephrine (B) and methanephrine (C) for the reference 
Table 3 Diagnostic sensitivity and specificity of measure-
ments of plasma metanephrines with and without methoxy-
tyramine.
 Sensitivity (%) Specificity (%)
 PPGLs HNPGLs No tumor
NMN and MN 97.2 (207/213) 22.1 (8/38) 95.9 (1641/1712)
NMN, MN and 
MTY
98.6 (210/213) 50.0 (19/38)* 95.1 (1628/1712) 
*P < 0.05, indicates significant difference compared to NMN and MN.
HNPGLs, head and neck paragangliomas; MN, metanephrine; MTY, 
methoxytyramine; NMN, normetanephrine; PPGLs, pheochromocytomas 
and paragangliomas.
population (REF), patients tested for PPGLs with no evidence of 
tumors (NO TUM) compared to patients with PPGLs and HNPGLs. 
Dashed horizontal lines designate upper cut-off values of 
reference intervals, which for normetanephrine range from 
0.55 nmol/L (100 pg/mL) in 5 -year-olds to 1.09 nmol/L (200 pg/mL) 
in 65 –year-olds as illustrated in Fig. 1. Median values are shown 
for each metabolite. Different symbols serve to illustrate subjects 
of the reference population or patients without tumors (solid 
gray dot) compared to patients with tumors and positive results 
for normetanephrine alone (solid black square), methoxytramine 
or methoxytyramine and normetanephrine (solid black upward 
triangle), metanephrine or metanephrine and normetanephrine 
(solid black downward triangle), all three metabolites (solid 
black diamond) or no metabolites (solid black dot).
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of methoxytyramine, the proportion of patients with 
PPGLs and combinations of positive test results increased 
from 49.3 to 70.9%, the latter comprising near equal 
proportions of patients with positive results for all three 
metabolites, positive results for normetanephrine and 
Figure 3
Receiver operating characteristic curves for diagnosis of PPGLs 
(A) and HNPGLs (B). Curves are shown for combinations of 
normetanephrine and metanephrine (lower curve) vs 
normetanephrine, metanephrine and methoxytyramine 
(upper curve). A full color version of this figure is available at 
http://dx.doi.org/10.1530/EJE-17-0077.
A
B
Figure 4
Relationships of fold increases of plasma normetanephrine 
above upper cut-offs vs fold increases above upper cut-offs for 
methoxytyramine (A) and metanephrine (B) for patient 
populations with and without PPGLs. Dashed vertical and 
horizontal lines to illustrate fold increases of 1.0 at upper 
cut-offs. Different symbols serve to illustrate patients without 
tumors (solid gray dot), patients with tumors and positive 
results for normetanephrine alone (solid black square), for 
methoxytramine or methoxytyramine and normetanephrine 
(solid black upward triangle), metanephrine or metanephrine 
and normetanephrine (solid black downward triangle), all 
three metabolites (solid black diamond) or no metabolites 
(solid black dot).
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metanephrine, and positive results for normetanephrine 
and methoxytyramine. Respective positive results in 
patients without tumors were between 0.06 and 0.29%. 
No patient, either with or without PPGLs, had positive 
results for both metanephrine and methoxytyramine.
Curves relating pretest prevalence to posttest positive 
predictive value, based on single positive results, indicated 
posttest probabilities ranging from 9 to 57% at pretest 
prevalences of 0.5–5% (Fig. 5). For positive results of both 
normetanephrine and metanephrine, observed in 49.3% 
of patients with compared to 0.18% of patients without 
tumors, curves were shifted to the left, ranging from 58 
to 94% at pretest prevalences of 0.5–5% (Fig.  5A). For 
combinations of positive results for methoxytyramine, 
normetanephrine and metanephrine posttest probabilities 
at a pretest prevalence of 0.5% ranged from 32% for 
normetanephrine and methoxytyramine positive pairs 
to 52% for normetanephrine and metanephrine positive 
pairs, and to 66% for positive triplets of all metabolites 
(Fig.  5B). At a pretest prevalence of 5%, posttest 
probabilities were increased further ranging from 83% for 
normetanephrine and methoxytyramine positive pairs, 
92% for normetanephrine and metanephrine positive 
pairs to 95% for the positive triplet combination.
Of the patients with PPGLs, 185 (86.9%) had 
increases of one or more of the metabolites in the triplet 
panel of more than 2-fold above UCs compared with 
only 3 patients without tumors (Fig. 3). Of these patients, 
146 had combined positive results for two or more 
metabolites compared to a single patient without tumors, 
a combination indicating close to 100% probability 
of disease.
Discussion
This study establishes utility of measurements of plasma 
methoxytyramine as an additional component of the 
standard panel of plasma-free metanephrines for the 
diagnosis of PPGLs. Although the measurements only 
modestly increase diagnostic sensitivity by enabling 
identification of rare tumors that produce solely 
dopamine, with appropriate reference intervals and 
preanalytical precautions, this detection can be achieved 
with a minimal loss in diagnostic specificity and no 
loss in diagnostic test performance as assessed by areas 
under ROC curves. More importantly, we show that the 
addition of methoxytyramine to the standard test panel 
improves diagnostic utility by increasing the proportion 
of patients with highly positive predictive test results 
Figure 5
Relationships of pretest prevalence of PPGLs vs posttest 
probability of the tumors. Posttest probabilities are shown 
according to positive results for normetanephrine or 
metanephrine (97.2% of all patients) vs positive results for 
both normetanephrine and metanephrine (49.3% of all 
patients) in panel A. In panel B, posttest probabilities are 
shown according to positive results for normetanephrine or 
metanephrine or methoxytyramine (98.6% of all patients) vs 
positive results for all three metabolites (23.0% of all patients) 
vs positive results for both normetanephrine and 
metanephrine (26.3% of all patients) and vs positive results 
for both normetanephrine and methoxytyramine (21.6% of all 
patients). Shaded areas serve to illustrate posttest 
probabilities at common pretest prevalence of 0.5% for 
patients tested because of signs and symptoms to 5% in 
patients with incidentalomas.
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who may benefit by a decision to immediately locate 
and manage the tumors rather than be subject to further 
follow-up biochemical testing to confirm or exclude 
disease. Our study also extends previous observations 
that measurements of methoxytyramine can be useful 
for identifying dopamine-producing HNPGLs (10), by 
significantly increasing test performance beyond that of 
the standard test panel.
Although there have been some previous reports 
on LC–MS/MS measurements of plasma metanephrines 
for diagnosis of PPGLs (18, 19), this is the first 
prospective study involving additional measurements of 
methoxytyramine in a large population of patients tested 
for the tumors. It is also the first to define and validate 
reference intervals for all three O-methylated metabolites 
that not only facilitate high diagnostic sensitivity but 
also enable this at a level of specificity associated with 
minimal false-positive results. This is important since 
low diagnostic specificity erodes confidence that positive 
results can indicate a tumor, leading to lack of motivation 
for follow-up (20). False-positive results, however, mainly 
reflect lack of adherence to preanalytical precautions, in 
particular sampling blood after a period of supine rest to 
lower sympathoneuronal release of norepinephrine and 
production of its O-methylated metabolite (21).
Reasonably high diagnostic specificity for 
measurements of normetanephrine is achieved by 
sampling blood in the supine position and use of age-
specific UCs for supine plasma concentrations that follow 
the age distribution of 97.5 percentiles, doubling between 
5 and 65  years. These age-specific UCs were initially 
established in a population of over 5000 subjects (15); they 
are further validated here for measurements by LC–MS/
MS. Harmonization of laboratory results between methods 
and laboratories has been facilitated over the past decade 
via an international inter-laboratory quality assurance 
program (22), allowing for improved comparisons of 
results between laboratories and minimized requirements 
for validation of transferred reference interval data.
For measurements of metanephrine and 
methoxytyramine, which are of secondary importance to 
normetanephrine for diagnosis of PPGLs, high diagnostic 
sensitivity can be maintained with minimal loss of 
specificity by establishing UCs using 99.5 percentiles or 
ranges in reference populations rather than commonly 
employed 97.5 percentiles. For measured concentrations 
of plasma methoxytyramine, which can be increased 
by the presence of dietary amine precursors (14), it is 
also critical that blood sampling is performed after an 
overnight fast (21). With these precautions and UCs in 
place, the present report establishes minimal proportions 
of false-positive results for all metabolites and even lower 
proportions of false-positives for 2 or more metabolites in 
the panel.
The rare nature of positive results involving increased 
plasma concentrations of two or more metabolites 
in patients without compared to those with PPGLs 
means that such findings are strongly predictive of a 
catecholamine-producing tumor. This is useful since at 
low pretest prevalences, even with diagnostic specificity 
approaching 95%, posttest predictive values of a positive 
result for a single metabolite can be insufficient for reliable 
confirmation of a tumor. Although pretest prevalences 
of PPGLs can run up to 5% in patients with adrenal 
incidentalomas (23), among unselected patients screened 
for PPGLs pretest prevalences range from 0.8% to 1.6% 
(24, 25, 26), which is in line with lower prevalences of 
PPGLs among hypertensives of up to 0.6% (27). As we 
show here, at such prevalences posttest probabilities may 
not reach more than 10% for single positive results.
The Endocrine Society Guidelines on PPGLs 
include recommendations that all positive biochemical 
results should be followed up, while imaging studies 
to locate tumors should not be initiated until there 
is clear biochemical evidence of a PPGL (4). This raises 
the question about what constitutes clear biochemical 
evidence. As outlined in those guidelines, increases 
of both normetanephrine and metanephrine provide 
such evidence. As we now outline here, the addition of 
methoxytyramine to the test panel increases to over 70% 
the proportion of patients with highly predictive positive 
results for multiple metabolites. For those patients, there 
should be no need to embark on confirmatory biochemical 
tests. Rather the immediate task is to locate the tumor.
Addition of methoxytyramine to standard tests 
of normetanephrine and metanephrine has already 
established utility, beyond screening for PPGLs, by 
pointing to possible metastatic disease (9) or the presence 
of mutations in genes for succinate dehydrogenase (8). 
While not the focus of the present study, this additional 
utility of methoxytyramine is also important when 
considering the addition of these measurements to 
the standard test panel routinely offered for diagnosis 
of PPGLs and particularly when there is additional risk 
of HNPGLs.
One limitation of our study relates to the follow-up of 
patients without a diagnosis of PPGLs to further exclude 
or confirm disease, this achieved in 63.4% of patients, 
with exclusion of PPGLs in 99.5% of those cases. Of the 
five patients in whom tumors were found on follow-up, 
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two were patients with false-negative results including 
one with an HNPGL and another with a small lymph 
node metastasis secondary to a previously resected 
adrenal pheochromocytoma. All the three other patients 
with PPGLs discovered on follow-up showed initial small 
increases in normetanephrine above UCs, illustrating the 
importance of not to ignore any patient with positive 
biochemical test results.
Although false-negative results are common among 
patients with HNPGLs (10), in this study involving 50% 
of patients, we confirm that false-negative results are rare 
for patients with PPGLs when employing measurements 
of plasma-free metanephrines and methoxytyramine. As 
shown here and elsewhere (28, 29), such negative results 
may be encountered in patients with small tumors or 
metastatic lesions (<1.5 cm) as well as in patients with 
non-functional PPGLs that do not synthesize, store or 
metabolize catecholamines. Non-functional tumors may 
reach a large size before diagnosis (29), as also indicated 
by the two cases in this series. Apart from these rare 
tumors, negative test results for plasma metanephrines 
and methoxytyramine reliably exclude all but the smallest 
of catecholamine-producing PPGLs.
In summary, while additional measurements of 
plasma methoxytyramine only modestly improve 
detection of PPGLs above that achieved using standard 
measurements of normetanephrine and metanephrine, 
the measurements are useful for the detection of HNPGLs. 
More importantly, inclusion of methoxytyramine enables 
more accurate discrimination of true-positive from false-
positive results. Specifically, even at pretest prevalences 
as low as 0.5%, combinations of positive results for any 
two or more of the three metabolites carry high positive 
predictive value that along with increases of 2-fold or 
more above UCs indicate close to 100% probability of 
tumors in nearly 70% of patients with PPGLs. It is however 
important to appreciate that these conclusions are only 
valid with accurate measurements of the metabolites, 
appropriate attention to preanalytics and correctly 
established reference intervals.
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